Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results

Preclinical data suggest that inhibition of the metabotropic glutamate receptor 5 (mGluR5) receptor might hold therapeutic benefits in Fragile X syndrome (FXS). Treatment of Fmr1 knockout mice with mGluR5-negative allosteric modulators (NAMs) has been reported to correct a broad range of phenotypes...

Descripción completa

Detalles Bibliográficos
Autores principales: Youssef, Eriene A, Berry-Kravis, Elizabeth, Czech, Christian, Hagerman, Randi J, Hessl, David, Wong, Chin Y, Rabbia, Michael, Deptula, Dennis, John, Amy, Kinch, Russell, Drewitt, Philip, Lindemann, Lothar, Marcinowski, Moritz, Langland, Rachel, Horn, Carsten, Fontoura, Paulo, Santarelli, Luca, Quiroz, Jorge A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770759/
https://www.ncbi.nlm.nih.gov/pubmed/28816242
http://dx.doi.org/10.1038/npp.2017.177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770759/
https://www.ncbi.nlm.nih.gov/pubmed/28816242
http://dx.doi.org/10.1038/npp.2017.177

Ejemplares similares